First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.
Adult
Aged
Antineoplastic Agents
/ administration & dosage
Female
Humans
Male
Maximum Tolerated Dose
Middle Aged
Neoplasms
/ drug therapy
Peripheral Nervous System Diseases
/ chemically induced
Polyketides
/ administration & dosage
Pyrones
/ administration & dosage
Treatment Outcome
Tubulin Modulators
/ administration & dosage
Young Adult
First-in-human
Microtubule inhibitor
PM060184
Phase I
Plocabulin
Solid tumors
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
25
07
2018
accepted:
02
10
2018
pubmed:
10
11
2018
medline:
7
2
2020
entrez:
10
11
2018
Statut:
ppublish
Résumé
Background Plocabulin (PM060184) is a novel marine-derived microtubule inhibitor that acts as an antitumor agent. This first-in-human study evaluated dose-limiting toxicities (DLT) to define the maximum tolerated dose (MTD) and phase II recommended dose (RD) of plocabulin given as a 10-min infusion on Day (D) 1, D8 and D15 every four weeks. Patients and methods Forty-four patients with advanced solid tumors received plocabulin following an accelerated titration design. Results Plocabulin was escalated from 1.3 mg/m
Identifiants
pubmed: 30411218
doi: 10.1007/s10637-018-0674-x
pii: 10.1007/s10637-018-0674-x
doi:
Substances chimiques
Antineoplastic Agents
0
Polyketides
0
Pyrones
0
Tubulin Modulators
0
plocabulin
52Y8L60CR7
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
674-683Références
Clin Cancer Res. 2009 Apr 15;15(8):2594-601
pubmed: 19351751
Ann Oncol. 2005 Jun;16(6):869-77
pubmed: 15855226
J Clin Oncol. 2006 Jun 20;24(18):2932-47
pubmed: 16717289
J Clin Oncol. 2004 Jun 1;22(11):2084-91
pubmed: 15169795
N Engl J Med. 2004 Jun 3;350(23):2343-51
pubmed: 15175436
ACS Chem Biol. 2013 Sep 20;8(9):2084-94
pubmed: 23859655
Cancer. 1989 Aug 15;64(4):801-5
pubmed: 2743273
Proc Natl Acad Sci U S A. 2014 Sep 23;111(38):13817-21
pubmed: 25114240
Lancet. 2011 Mar 12;377(9769):914-23
pubmed: 21376385
J Clin Oncol. 2008 Apr 1;26(10):1642-9
pubmed: 18375893
Semin Oncol. 2006 Feb;33(1):15-49
pubmed: 16473643
Support Care Cancer. 2014 Jul;22(7):1999-2007
pubmed: 24728618
Br J Clin Pharmacol. 2017 Feb;83(2):255-268
pubmed: 27620987
J Clin Oncol. 2000 Mar;18(6):1212-9
pubmed: 10715290
Eur J Cancer. 1999 Sep;35(9):1338-42
pubmed: 10658524
Ann Oncol. 2012 Dec;23(12):3116-22
pubmed: 22865779
Am J Nephrol. 2010;31(3):209-13
pubmed: 20029177
Front Pharmacol. 2017 Feb 24;8:86
pubmed: 28286483
Acta Oncol. 2007;46(8):1131-7
pubmed: 17851880
Biochem Pharmacol. 2014 Apr 1;88(3):291-302
pubmed: 24486569
Mol Cancer Ther. 2014 Feb;13(2):275-84
pubmed: 24435445
BMC Cancer. 2018 Feb 7;18(1):164
pubmed: 29415678
J Am Chem Soc. 2013 Jul 10;135(27):10164-71
pubmed: 23750450